BC
SUPN icon

Brookfield Corp’s Supernus Pharmaceuticals SUPN Stock Holding History

Brookfield Corp’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,589
Closed -$460K – 733
2022
Q3 		$460K Buy
+13,589
New +$442K ﹤0.01% 574

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return

Brookfield Corp's SUPN Position: Q4 2022 in Review

Brookfield Corp sold out of Supernus Pharmaceuticals (SUPN) in Q4 2022, closing a stake of 13,589 shares — an estimated $460K sold.

Brookfield Corp first reported a position in SUPN in Q3 2022 and held it in 1 quarter. The position peaked at $460K in Q3 2022. 262 funds tracked by Wall St. Rank hold SUPN as of Q4 2022.

  • Brookfield Corp reported no remaining Supernus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Brookfield Corp sold 13,589 Supernus Pharmaceuticals shares in Q4 2022, an estimated $460K.
  • Brookfield Corp first reported a position in Supernus Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Brookfield Corp's Supernus Pharmaceuticals position peaked at $460K in Q3 2022.
  • 262 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2022.

Based on Brookfield Corp's 13F filing for Q4 2022, filed 14 Feb 2023.